Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Equity Ratio (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Equity Ratio for 13 consecutive years, with 0.77 as the latest value for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 1.96% to 0.77 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.77, a 1.96% decrease, with the full-year FY2025 number at 0.77, down 1.96% from a year prior.
  • Equity Ratio was 0.77 for Q4 2025 at Iovance Biotherapeutics, down from 0.78 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.81 in Q1 2023 to a low of 0.75 in Q4 2023.
  • A 3-year average of 0.78 and a median of 0.78 in 2024 define the central range for Equity Ratio.
  • Biggest YoY gain for Equity Ratio was 4.16% in 2024; the steepest drop was 3.31% in 2024.
  • Iovance Biotherapeutics' Equity Ratio stood at 0.75 in 2023, then increased by 4.16% to 0.78 in 2024, then fell by 1.96% to 0.77 in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Equity Ratio are 0.77 (Q4 2025), 0.78 (Q3 2025), and 0.77 (Q2 2025).